DRL
Location
Vlaams Brabant
Founded
1980-09-05
Website
Risk Signals
105 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Furniture, Catalog and Mail-Order Houses), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about DRL
Live alerts from global media, monitored by Business Radar
2025-05-12 (businessupturn.com)
Nomura bullish on Dr. Reddy's after strong Q4; raises target price to Rs 1,575 on FY26 growth optimism |
Nomura has upgraded its outlook on Dr. Reddy's Laboratories, reaffirming a 'Buy' rating and raising the target price to ₹1,575, following a stronger-than-expected Q4 performance and optimistic FY26 guidance.DRL reported a net profit of ₹1,587.3 crore
Read more
2024-12-19 (financialexpress.com)
Dr Reddy's shares jump over 4 per cent on upgrade by Nomura - Market News | The Financial Express
The underperformance persists despite a 22.6% earnings compounded annual growth rate (CAGR) expected between FY20 and FY25F and upward revisions to FY25/26 earnings estimates.
Read more
2024-11-06 (thehansindia.com)
Dr Reddy's clocks 16.51% increase in Q2 revenues
Y-o-y growth primarily driven by global generics revenuesQoQ growth primarily driven by generics revenues in emerging marketsPharma Services and Active Ingredients rose 16.76%Revenues from global generics surged 17.17%
Read more
2024-07-27 (business-standard.com)
Dr Reddy's Laboratories Q1 result: Net profit dips 0.90%, revenue up 13.88%
DRL's growth was primarily driven by the robust performance of the global generics business, particularly in North America and India
Read more